Confirmation of this was obtained using treatment with the FDA approved HDi, SAHA (Vorinostat), which also resulted in increased IL-23R expression in both of the NSCLC cell lines examined (Figure 2B) (p < 0.05). Here, IL23R is linked to non-small cell lung carcinoma.